| GENE_SYMBOL |
DRUG_NAME |
Ki (nM) |
IC50 (nM) |
Kd (nM) |
EC50 (nM) |
Potency (nM) |
AC50 (nM) |
Datasource |
| ATP1A2 |
2,2-Difluoro-6-[(4,5-dimethoxy-3-methyl-2-pyridinyl)methylsulfinyl]-5H-1,3-dioxolo[4,5-f]benzimidazole |
NA |
1000000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
5-Difluoromethoxy-6-methoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole |
NA |
251188.64 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-6-fluoro-1H-benzimidazole |
NA |
398107.17 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
2,2-Difluoro-6-[(4,5-dimethoxy-2-pyridinyl)methylsulfinyl]-5H-1,3-dioxolo[4,5-f]benzimidazole |
NA |
1000000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
2,2-Difluoro-6-[(4-methoxy-2-pyridinyl)methylsulfinyl]-5H-1,3-dioxolo[4,5-f]benzimidazole |
NA |
1000000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
1-[(17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone |
NA |
400000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
32,33-dihydro-31-hydroxymanzamine A |
NA |
150000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
2-((2E,7E)-3,7-dimethyl-9-((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)nona-2,7-dienyl)benzene-1,4-diol |
NA |
117000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
Pantoprazole |
NA |
199526|199526.23 |
NA |
NA |
NA |
NA |
PubChem|TTD |
| ATP1A2 |
(3-methylimidazol-4-yl)-(9H-pyrido[3,4-b]indol-1-yl)methanone |
NA |
150000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
Manzamine A |
NA |
150000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
1-[(5R,8R,9S,10S,13R,14R,17S)-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone |
NA |
200000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
(1R,3R,4S,8R,9S,12Z,21R,22R,24R,26S,30R,31S,34Z,43R,44R,48R)-50,55-bis(9H-pyrido[3,4-b]indol-1-yl)-2,25-dioxa-7,18,29,40-tetrazaundecacyclo[24.19.3.23,24.29,21.231,43.118,22.140,44.01,29.07,24.08,22.030,44]hexapentaconta-12,34,50,55-tetraene-4,9,31,48-tetrol |
NA |
150000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A2 |
4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl-(3-methylimidazol-4-yl)methanone |
NA |
150000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
(3S,5R,8R,9S,10S,13R,14S,17E)-17-[(2E)-2-[3-(dimethylamino)propoxyimino]ethylidene]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14-diol |
NA |
160000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
5-Difluoromethoxy-2-[(4,5-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole |
NA |
316227.77 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
(3S,4S,5R,6R,7R,8R,9S,10R,13R,14S,17R)-17-[(2S,3R,4R,5S)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-3,4,6,7-tetrahydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one |
NA |
128000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
(3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-17-[(2S,3R,4R)-3,4-dihydroxy-6-methylheptan-2-yl]-3,4,6,7-tetrahydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one |
NA |
128000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
(3S,4S,5R,6R,7R,8R,9S,10R,13R,14S,17R)-3,4,6,7-tetrahydroxy-17-[(2R,4S,5S)-4-hydroxy-5,6-dimethylheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one |
NA |
128000 |
NA |
NA |
NA |
NA |
TTD |
| ATP1A3 |
sodium;[(3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-17-[(2S,3R,4R,5S)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-3,4,6-trihydroxy-10,13-dimethyl-15-oxo-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-7-yl] sulfate |
NA |
128000 |
NA |
NA |
NA |
NA |
TTD |